Evaluation of a new random-access HBV DNA molecular assay: The VERIS HBV assay.

Résumé : Detection and quantification of HBV DNA are essential to diagnose chronic HBV infection, monitor the virological response to treatment and the possible selection of resistant viruses in order to tailor therapy. The VERIS/MDx System HBV Assay is a random-access system that quantifies HBV DNA in clinical samples using unique single sample and reagent access during the workflow process without the need to reload other tests and delivers results within 1.2h following sampling.
Type de document :
Article dans une revue
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2017, 92, pp.69-74
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01528451
Contributeur : Slim Fourati <>
Soumis le : lundi 29 mai 2017 - 10:29:10
Dernière modification le : mardi 30 mai 2017 - 01:08:16

Identifiants

  • HAL Id : inserm-01528451, version 1
  • PUBMED : 28549336

Collections

Citation

Slim Fourati, Dominique Challine, Jean-Dominique Poveda, Syria Laperche, Sandrine Rallier, et al.. Evaluation of a new random-access HBV DNA molecular assay: The VERIS HBV assay.. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2017, 92, pp.69-74. 〈inserm-01528451〉

Partager

Métriques

Consultations de la notice

73